

Date: 4 August 2022

Re: Freedom of Information Request
Ref: 230-2022

Thank you for your email dated the 5th July 2022, requesting information in relation to Patients treated within your trust.

The information you require is as follows:

1) In total, over the past 4 months, how many patients have been treated for the following diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa)?

In the last 4-months there has been one patient with a non-cancer diagnosis of Psoriasis; they have not received any of the listed treatment options.

2) Of these five, how many of each received the following products:

- Adalimumab (Humira)
- Adalimumab Biosimilar
- Etanercept (Enbrel)
- Etanercept Biosimilar
- Infliximab (Remicade)
- Infliximab biosimilar
- Golimumab (Simponi)
- Tofacitinib (Xeljanz)
- Ustekinumab (Stelara)
- Vedolizumab (Entyvio)
- Filgotinib (Jyseleca)
- Abatacept (Orencia)
- Baricitinib (Olumiant)
- Certolizumab Pegol (Cimzia)
- Rituximab (MabThera)

- Rituximab Biosimilar
- Tocilizumab (RoActemra)
- Sarilumab (Kevzara)
- Apremilast (Otezla)
- Secukinumab (Cosentyx)
- Isekizumab (Taltz)
- Guselkumab (Tremfya)
- Brodalumab (Kyntheum)
- Risankizumab (Skyrizi)
- Tildrakizumab (Ilumetri)
- Upadacitinib (Rinvoq)
- Bimekizumab (Bimzelx)

N/A

3) Could you please provide the number of these patients that were treated within the gastro department (still split by disease and treatment).

N/A

4) Over the same time period, how many patients for each of the five diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa) received the following treatments as their first ever biologic treatment?

- AxSPA
- PsA
- PsO

N/A

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision.

The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://forms.office.com/r/eLzHXi49Ea>



Kind Regards,

The Information Governance Team
Contact Email: ccf-tr.foi@nhs.net